A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer (ARC-9)
Study of AB928 in Combination with Other Therapies for Patients with Metastatic Colon Cancer (mCRC)
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT5564
U.S. Govt. ID: NCT04660812
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to help understand whether an investigational drug, AB928 (referred to as etrumadenant and etruma), is safe and effective when given in combination with other therapies to patients with metastatic colorectal cancer (mCRC). Etruma may be combined with other investigational drugs, known as AB680 and zimberelimab (AB122), or maybe combined with drugs that are approved by the United States Food and Drug Administration (U.S. FDA) and other government agencies to treat mCRC.
This study is closed
Gulam Manji, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have metastatic colorectal adenocarcinoma (colon cancer)? Yes No
Is your life expectancy longer than 3 months? Yes No
Are you able to take oral medications? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator